{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:52:55Z","timestamp":1791085975586,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106915","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:16:59Z","timestamp":1787923019000},"page":"106915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-3499","authenticated-orcid":false,"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-4434","authenticated-orcid":false,"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1519","authenticated-orcid":false,"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5596-8807","authenticated-orcid":false,"given":"Hazza","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-5524","authenticated-orcid":false,"given":"Lize","family":"van Vulpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-8518","authenticated-orcid":false,"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8195-9621","authenticated-orcid":false,"given":"Samya","family":"Obaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-7947","authenticated-orcid":false,"given":"Sanjay","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-163X","authenticated-orcid":false,"given":"Sophie","family":"Susen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-4718","authenticated-orcid":false,"given":"Steven R.","family":"Lentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Roar","family":"H\u00f8gh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilgiz","family":"Rakhmatullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106915_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"suppl 6","key":"10.1016\/j.rpth.2026.106915_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106915_bib3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial","volume":"146","author":"Matino","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106915_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","article-title":"Concizumab: a novel anti-TFPI therapeutic for hemophilia","volume":"5","author":"Shapiro","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106915_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106915_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106915_bib8","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106915_bib9","first-page":"369","article-title":"Investigation into the acceptability of moderate-to-large volume subcutaneous injections in healthy volunteers: results from a single-center randomized controlled study","volume":"17","author":"Akinseye","year":"2024","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.rpth.2026.106915_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41120-025-00108-4","article-title":"Injection site reactions of biologics and mitigation strategies","volume":"11","author":"Zhi","year":"2025","journal-title":"AAPS Open"},{"key":"10.1016\/j.rpth.2026.106915_bib11","article-title":"Patient-reported outcome measures in adults with hemophilia: a scoping review","volume":"1","author":"Bai","year":"2025","journal-title":"Healthc Rehabil"},{"key":"10.1016\/j.rpth.2026.106915_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/17474086.2024.2365929","article-title":"Outcome measures in hemophilia: current and future perspectives","volume":"17","author":"Benemei","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106915_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102181","article-title":"Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults","volume":"7","author":"Persson","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106915_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/JBM.S260923","article-title":"Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia A: a review of the evidence","volume":"12","author":"Dargaud","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2026.106915_bib15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106915_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107162","article-title":"Model-informed drug development of Mim8 \u2013 a next-generation bispecific antibody for treatment of haemophilia A","volume":"212","author":"Kreilgaard","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.rpth.2026.106915_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2517384","article-title":"Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors","volume":"394","author":"Mancuso","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106915_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41687-023-00550-6","article-title":"Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM)","volume":"7","author":"Brod","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.rpth.2026.106915_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med Care"},{"key":"10.1016\/j.rpth.2026.106915_bib20","doi-asserted-by":"crossref","unstructured":"Kenet G, Berrueco R, Fijnvandraat K, Kj\u00f6llerstr\u00f6m P, Luciani M, Mahlangu J, et al. Denecimig (Mim8) prophylaxis in children with haemophilia A with or without factor VIII inhibitors. Res Pract Thromb Haemost. In press. https:\/\/doi.org\/10.1016\/j.rpth.2026.106914","DOI":"10.1016\/j.rpth.2026.106914"},{"key":"10.1016\/j.rpth.2026.106915_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106915_bib22","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.106915_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106915_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.rpth.2026.106915_bib25","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106915_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1932296817735121","article-title":"Impact of injection speed, volume, and site on pain sensation","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.rpth.2026.106915_bib27","series-title":"Expedited learning and enhanced usability of a pre-filled Mim8 pen-injector for the management of haemophilia A. Presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 congress; Milan, Italy","author":"Shastri","year":"2025"},{"key":"10.1016\/j.rpth.2026.106915_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/cts.12794","article-title":"Annual bleeding rates: pitfalls of clinical trial outcomes in hemophilia patients","volume":"13","author":"Keipert","year":"2020","journal-title":"Clin Transl Sci"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:13:48Z","timestamp":1791083628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035739"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106915","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106915"}}